NCT07945353
Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants will receive oral orelabrutinib for 12 weeks, followed by 4 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 2 fractions. Radiotherapy will be initiated within 4 weeks after completion of orelabrutinib. Response will be assessed after treatment, and additional local radiotherapy or salvage treatment may be administered according to the predefined response-based management strategy.
Participants will receive 24 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 12 fractions. Radiotherapy will be initiated within 4 weeks after randomization. Patients with inadequate response may receive salvage treatment at the investigator's discretion.
Drugs: Orelabrutinib
Radiation: 4 Gy Involved-Site Radiotherapy (ISRT), 24 Gy Involved-Site Radiotherapy (ISRT)
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China